Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial

Gael B. Morrow* (Corresponding Author), Timea Feller, Zoe McQuilten, Elizabeth Wake, Robert A. S. Ariëns, James Winearls, Nicola J. Mutch, Mike A. Laffan, Nicola Curry

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)
4 Downloads (Pure)

Abstract

Fibrinogen is the first coagulation protein to reach critical levels during traumatic haemorrhage. This laboratory study compares paired plasma samples pre- and post-fibrinogen replacement from the Fibrinogen Early In Severe Trauma studY (FEISTY; NCT02745041). FEISTY is the first randomised controlled trial to compare the time to administration of cryoprecipitate (cryo) and fibrinogen concentrate (Fg-C; Riastap) in trauma patients. This study will determine differences in clot strength and fibrinolytic stability within individuals and between treatment arms.
Original languageEnglish
Article number290
Number of pages12
JournalCritical Care
Volume26
Issue number1
DOIs
Publication statusPublished - 26 Sept 2022

Bibliographical note

Acknowledgements
We acknowledge the Aberdeen Microscopy and Histology Core Facility and thank Judith de Vries for her guidance in analysing the confocal images. We thank Megan Simpson for measuring PAI-1 and uPA antigen levels in the fibrinogen preparations. We thank all of the FEISTY research staff who collected and processed the patient samples.

Funding
This work was supported by research grants from CSL Behring and Tenovus Scotland.

Data Availability Statement

For original data, please contact gael.morrow@ndcls.ox.ac.uk.

Keywords

  • Fibrinogen
  • cryoprecipitate
  • clot structure
  • Trauma coagulopathy
  • fibrinolysis

Fingerprint

Dive into the research topics of 'Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial'. Together they form a unique fingerprint.

Cite this